Nanobiotech Pioneers Predict Nanomedicine Impact within Five Years
February 12, 2004 | Source: KurzweilAI
Ground-breaking nanotechnology researcher Ralph C. Merkle, Ph.D., and the father of nanomedicine Robert A. Freitas, Jr., JD, are among the industry heavyweights who weighed in with NanoBiotech News on the state of nanomedicine and where it’s headed.
“The evolutionary spectrum in nanomedicine will start at the sensing and diagnostics end and move into therapeutics over time,” predicts Freitas.
“The applications nearest to commercialization are probably the fullerene-related and dendrimer-related drugs. Nanoshells are making their way toward commercialization, but the fullerenes and dendrimers are probably closest in terms of somebody making money from a product.”